Read about the safety information of LUCENTIS
LUCENTIS® (ranibizumab injection) is a prescription medicine for the treatment of patients with wet age-related macular degeneration (wAMD), macular edema following retinal vein occlusion (RVO), and diabetic macular edema (DME).
LUCENTIS is a prescription medication given by injection into the eye, and it has side effects. Some LUCENTIS patients have had detached retinas and serious infections inside the eye. You should not use LUCENTIS if you have an infection in or around the eye or are allergic to LUCENTIS or any of its ingredients.
Uncommonly, LUCENTIS patients have had serious, sometimes fatal, problems related to blood clots, such as heart attacks or strokes.
Some patients have had increased eye pressure before and within 1 hour of an injection.
Serious side effects include inflammation inside the eye and, rarely, problems related to the injection procedure, such as cataracts. These side effects can make your vision worse.
The most common eye-related side effects are increased redness in the white of the eye, eye pain, small specks in vision, and increased eye pressure. The most common non-eye-related side effects are nose and throat infections, headache, lung/airway infections, and nausea.
If your eye becomes red, sensitive to light, or painful, or if you have a change in vision, call or visit your eye doctor right away.
For additional safety information, please talk to your doctor and see the LUCENTIS full prescribing information.
The information contained in this section of the site is intended for U.S. healthcare professionals only. Click "OK" if you are a healthcare professional.
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech, Inc. does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.
Wet age-related macular degeneration(wet AMD)
Macular edema following retinal vein occlusion(RVO)